March 12, 2018 / 11:10 AM / 7 months ago

BRIEF-Alnylam Retains Global Rights To Lumasiran, Investigational RNAi Therapeutic For Treatment Of Primary Hyperoxaluria Type 1

March 12 (Reuters) - Alnylam Pharmaceuticals Inc:

* ALNYLAM RETAINS GLOBAL RIGHTS TO LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)

* ALNYLAM PHARMACEUTICALS INC - ‍COMPANY PLANS TO ACCELERATE DEVELOPMENT WITH PHASE 3 START IN LATE 2018​

* ALNYLAM PHARMACEUTICALS INC - ‍LUMASIRAN GRANTED BREAKTHROUGH THERAPY DESIGNATION BY UNITED STATES FOOD AND DRUG ADMINISTRATION​

* ALNYLAM PHARMACEUTICALS INC - ‍SANOFI GENZYME HAS DECLINED ITS OPT-IN FOR DEVELOPMENT AND COMMERCIALIZATION OF LUMASIRAN​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below